Aliskiren misses ASPIRE endpoint

Novartis AG (NYSE:NVS; SIX:NOVN) said aliskiren plus standard therapy missed the primary endpoint in the Phase III ASPIRE trial to prevent left ventricular remodeling in high-risk post-acute myocardia...